摘要：古剑奇谭...

3c认证

杭州“新八骏”掌舵，“高光谱AI双星”齐射_我的网站

nba

一 | 杭州“新八骏”现象涌现后，首次有成员完成“上天”之举。 Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。8月5日10时38分许，山东省海阳市近海海域，捷龙三号遥十二运载火箭腾空而起。两颗高光谱卫星“东方星链05/06星”成功进入预定轨道。这两颗星由杭州“新八骏”之一，西湖区企业地卫二提供AI能力和国际合作。

二 | 给这两颗卫星“画个像”，最直观的感受就是轻，在同类遥感卫星里算妥妥的“轻量级”。对比一下，美国WorldView-3重达2800公斤，欧空局的哨兵二号单颗也要1140公斤左右，而这两颗卫星约是欧美同类卫星的五分之一。业内有个粗略算法：把1公斤载荷送到700公里轨道，成本大概5万块。重量一轻，发射成本自然大幅下降。那轻了，能力会不会打折？恰恰相反。全球对地观测领域，美国的Landsat和欧洲哨兵二号一直是公认的标杆，但跟这两位“老大哥”同台比拼，“东方星链05/06星”在多个维度上已经实现了超越。

三 | 工作人员正在转运卫星受访者供图工作人员正在转运卫星受访者供图从分辨率来看，分辨率越高，能捕捉的地表细节就越多。“东方星链05/06星”比“哨兵二号”的10米高一倍，比美国Landsat的15米和30米高两到五倍；同时，它的宽幅是300公里，相当于一次扫描，能覆盖从杭州到南京的距离。光谱通道是卫星看世界的“眼睛”，“眼睛”越多自然看得更分明。“东方星链05/06星”配备了22个精密校准光谱通道，高于欧洲哨兵二号的13个和美国Landsat的11个。“在300公斤的整星上，它同时做到了看得清、看得宽、看得准。”地卫二相关负责人这样描述，“说到底，就是用更低的成本，干成了更难的事。

四 | ”不光拍得清，而且算得快。

五 | 遥感卫星有个困境，看得越宽、拍得越清，数据量就越大，地面处理起来就越吃力。

六 | 从卫星过境到用户拿到结论，往往需要数小时甚至数天。

七 | “这两颗卫星搭载了地卫二自主研发的‘弦’人工智能计算单元，拥有400TOPS星载AI算力，这是全球所有高光谱卫星中算力最高的卫星。”地卫二技术总监唐振坤介绍，高算力让卫星在轨就能完成数据处理，只把“有效信息”传回地面，从“数天/ 小时级”压缩至“分钟级”，数据利用率从不足10%提升至80%以上，业务处理效率较人工判读提升5倍以上。正是“更轻”与“更智”的结合，让这两颗卫星从“看得清”升级到“看得懂”，成为高光谱卫星从“数据采集”迈向“智能服务”的关键一步。据悉，“东方星链05/06星”双星组网后，将5天覆盖全球一次，在动态监测中及时发现变化。这就好比在给地球做CT，结合星上的“绿水青山大模型”，它们可以观测及分析山、水、林、田、湖、草、沙、滨海所有地表及其要素资源的现状及变化，比如监测庄稼的氮磷钾含量和作物长势，发现湖泊和土壤的污染情况。“这是我国高光谱遥感技术的重大突破。”国家最高科学技术奖获得者、两院院士李德仁评价，“它们是国际顶尖商业高光谱卫星，卫星不再只是记录像素的相机，而是开始理解自己所看到的一切。” 卫星出厂受访者供图卫星出厂受访者供图这次发射的两颗卫星，从出厂开始就带着国际订单。一颗叫“撒马尔罕-2028”，乌兹别克斯坦航天局跟地卫二合作，将专门服务该国棉花产业从播种到收获的全过程，全程监测。另一颗叫“楠榜一号”，是印度尼西亚楠榜省的卫星，负责当地的农业监测和灾害预警。

八 | 这两颗星也是“全球数贸AI星座”的首发星。按照计划，它们将面向全球提供对地观测服务，帮助有需求的国家获得遥感数据与智能分析能力。这些数据后续也可用于跨境贸易的数字化管理，以及全球范围的数据交换与流通。同时，这两颗星的发射成功，意味着“太空之弦计算星座”开始组网。按照规划，这个星座将部署超过1000颗太空智能体，建设一套覆盖全球的太空计算基础设施。完整的星座方案和千星组网路线图，计划于2026年9月正式发布。这些卫星背后的产业支撑，就在杭州。